FDA Approves Ustekinumab Biosimilar Yesintek

FDA Approves Ustekinumab Biosimilar Yesintek

This is the sixth ustekinumab biosimilar approval in the United States, with the drug set to launch in 2025.

Sixth Stelara Biosimilar, Yesintek, FDA-Approved

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Biocon lands FDA approval for another Stelara biosimilar

Biocon Biologics scored an FDA approval for its Stelara biosimilar, marketed as Yesintek, the company announced Monday. Biocon entered into a settlement and licensing agreement with Johnson & Johnson, which owns ...

FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

FDA Approves Ustekinumab-kfce as Sixth Biosimilar to Stelara

The biosimilar is approved for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

J&J Seeks FDA Approval for TREMFYA in Children with Psoriasis, Arthritis Treatment

Johnson & Johnson submits applications to expand TREMFYA treatment to children with plaque psoriasis and juvenile psoriatic arthritis, backed by Phase 3 study data.